Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Business & Industry
- Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial
- Pfizer and BioNTech publish results of study showing COVID-19 vaccine elicits antibodies that neutralize pseudovirus bearing the SARS-CoV-2 U.K. strain spike protein
- Roche confirms US government agreement to purchase additional doses of Regeneron's casirivimab and imdevimab
- Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
- Bayer transforms pharma business through breakthrough innovation in healthcare
Research & Development
- Obesity, impaired metabolic health and COVID-19
- COVID-19 has multiple faces
- Metformin use reduces risk of death for patients with COVID-19 and diabetes
- New England Journal of Medicine publishes COVID-19 treatment trial results
- Scientists identify 'immune cop' that detects SARS-CoV-2
- New findings help explain how COVID-19 overpowers the immune system
- New virtual screening strategy identifies existing drug that inhibits COVID-19 virus
Conferences & Events
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
- Wearable Injectors and Connected Devices Conference 2020
Regulatory Affairs
- EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
- FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
- Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
- FDA takes key action in fight against COVID-19 by issuing Emergency Use Authorization for first COVID-19 vaccine
- EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2